• Tango Therapeutics reported an 82% response rate for vopimetostat with daraxonrasib in 22 evaluable patients with MTAP-deleted pancreatic cancer.
• The nine-month progression-free survival rate reached 88%; no disease progression occurred in second-line patients.
• No treatment-related discontinuations occurred at dose level 1; no grade 4 or 5 treatment-related adverse events were reported.
• The Phase 3 strategy uses response rate and progression-free survival as dual primary endpoints, based on regulatory discussions.
• A $1 billion balance sheet is expected to support late-stage pancreatic cancer development and ongoing work.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.